NICU Early Onset Sepsis (EOS <72 hours of life)





- ECHO
- Initiating prostaglandin infusion

Early Onset Sepsis Evaluation & Antibiotic Recommendations



Evaluation:

- CBC at 6 12 hours of life (HOL); if > 12 HOL, collect specimen at evaluation initiation
 - Consider LP and CSF studies
 - Positive blood culture
 - If not pretreated with antibiotics: gram stain and culture are first priority
 - If pretreated with antibiotics: CSF and cell count are first priority
 - Apnea in preterm/term infant
 - Suspected/confirmed seizures
- Critically ill-appearing infant
- Consider HSV studies and Acyclovir
- HSV 1&2 NAAT surface cultures, HSV PVR plasma, CSF sample for HSV PCR, ALT
- In the case of multiples, if one infant is diagnosed with EOS, the other infant(s) should be monitored closely and evaluated/treated empirically if any
 sign of illness occurs due to increased risk factors
- If a patient has a central line in place at the time of a positive blood culture, removal of the line should be considered unless additional intravenous access is not available

Antibiotic Management:

- Ampicillin 100 mg/kg/dose IV Q8 hours
- Gentamicin 4 mg/kg/dose IV Q36 hours < 28 weeks OR Q24 hours ≥ 28 weeks

Negative Cultures WITH concern for clinical sepsis:

- Suspected sepsis based on clinical status and other lab results, but without a positive culture, should be treated with Ampicillin and Gentamicin for 7 days
- Therapeutic drug monitoring of Gentamicin as listed below

Negative cultures WITHOUT suspicion for clinical sepsis:

- If blood culture (+/- CSF culture) is obtained appropriately and prior to the initiation of antibiotics, should continue for a minimum of 48 hours
 pending results
- At 48 hours, unless there is a site-specific infection and if the sterile body culture(s) remain negative, antibiotics may be discontinued
- The infant and sterile culture results should be monitored for any change in status

Positive cultures:

(Therapeutic Drug Monitoring of Gentamicin)

Indicated for patients continuing on Gentamicin for > 48 hours due to either suspected clinical sepsis or culture-positive sepsis

- Draw trough level if therapy is to continue > 3 days or if the patient is critically ill to ensure non-toxic level
- Check a trough with 3rd or 4th dose, after dose adjustment, or if renal function changes significantly
- Timing of serum samples:
 - Draw trough immediately before dose is given (normal trough < 1.5 mg/L)
 - Draw peak 30 min after infusion is complete. Discuss results with pharmacist
- If both peak and trough are drawn, recommend obtaining both levels around same dose (trough, dose, peak) to achieve most accurate kinetics
- Please check with pharmacist with any questions concerning levels and goals of therapy

Group B Strep

- Ampicillin is drug of choice
- 10 days from first negative blood culture (2 negative blood cultures before discontinuing Ampicillin)
- 14 days minimum for meningitis
 - Consult Infectious Disease
 - Consider repeat LP 24-48 hours into therapy
 - Close follow-up testing (hearing, neurologic, development) for any patient diagnosed with meningitis

Listeria

- Combination therapy of Ampicillin and Gentamicin is recommended
- 14 days for bacteremia
- 21 day minimum for meningitis
 - Consult Infectious Disease
 - Consider diagnostic imaging near end of treatment course to assess for parenchymal involvement

Other Gram-Positive Organisms (i.e., Enterococcal and other Streptococcal species)

- Initial empiric therapy with Ampicillin and Gentamicin (should be continued with coverage narrowed based on susceptibilities)
- *Varying degrees of resistance warrants Infectious Disease consult

Gram-Negative Organisms

- Bacteremia alone should be treated with Ampicillin and Gentamicin, or a cephalosporin (i.e. cefepime) based on susceptibilities for 10 14 days
 - Meningitis should be treated with Ampicillin or a cephalosporin (i.e. cefepime) based on susceptibilities for a minimum of 21 days
 - Gentamicin should be considered initially if in combination with a cephalosporin as empiric therapy until susceptibilities are available
 Consult Infectious Disease to guide meningitis treatment
 - Consider repeat LP 24 48 hours into therapy
 - Close follow-up testing (hearing, neurologic, development) is warranted for patient treated for gram-negative meningitis
- ID consult recommended for any infection involving multi-resistant organisms or ESBL-producing infection

Fungal Infections = IMMEDIATE Infectious Disease consult

Metrics



Contributing Members



Ashley Ross, MD, - Neonatology Ankita Shukla, MD – Neonatology Stephanie Korff, MD - Neonatology Nidhi Agarwal, MD – Neonatology Sabra Curry, APRN -Neonatology Phillip Rampey, NICU Pharmacist Ellen Mallard, RN – Interim Director NICU Caleb McMinn, PharmD – Inpatient Antimicrobial Stewardship Holly Maples, PharmD – Director, Antimicrobial Stewardship Emily Rader, MSN – Manager, Clinical Effectiveness & Outcomes Sophia Blythe, MHA – Project Coordinator, Clinical Effectiveness & Outcomes